A new drug to enhance weight loss and metabolic benefits for diabetes treatment
A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1
This study is looking at a new version of a hormone called GIP that could help diabetes medications work better, making it easier for people with diabetes to manage their blood sugar and lose weight.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Velum, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10626143 on NIH RePORTER |
What this research studies
This research focuses on developing a modified version of the glucose-dependent insulinotropic peptide (GIP) to enhance the effects of existing diabetes medications. By making GIP resistant to degradation in the body, the researchers aim to improve its effectiveness in promoting weight loss and managing blood sugar levels. The project involves creating and testing various GIP derivatives to identify the most promising candidates for further clinical trials. Patients may benefit from a new treatment option that could improve their metabolic health and aid in weight management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with obesity and Type 2 Diabetes who are seeking new treatment options.
Not a fit: Patients who do not have obesity or Type 2 Diabetes may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective treatment for obesity and Type 2 Diabetes, potentially leading to significant weight loss and improved metabolic health.
How similar studies have performed: Other research has shown promise in enhancing the effects of diabetes medications through similar approaches, indicating potential for success in this area.
Where this research is happening
Cambridge, United States
- Velum, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Kumar, Krishna — Velum, INC.
- Study coordinator: Kumar, Krishna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.